echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Beida Pharmaceuticals BPI-361175 tablets obtained the U.S. FDA New Drug Clinical Trial Approval Notice

    Beida Pharmaceuticals BPI-361175 tablets obtained the U.S. FDA New Drug Clinical Trial Approval Notice

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 5, Betta Pharmaceuticals issued an announcement stating that the company's application for clinical trials of BPI-361175 tablets has been approved by the US FDA and is intended to be used for the treatment of non-small cell lung cancer carrying EGFRC797S mutations and other EGFR-related mutations


    BPI-361175 is a new molecular entity with completely independent intellectual property rights independently developed by Betta Pharmaceuticals.


    In February 2021, the company obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration on BPI-361175 tablets


    As of the disclosure date of this announcement, domestic and foreign drugs targeting EGFRC797S mutations are in preclinical

    Or in the early clinical stage, there is no drug on the market


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.